[Association of antiagregants: when and how].
Aterothrombotic disease (coronary, cerebrovascular and peripheral artery disease) is the most common cause of mortality and disability in the world, antiaggregants representing one of its therapeutic and preventive pillars. We have drugs at present that act at different levels of platelet aggregation (COX inhibitors as well as inhibitors of phosphodiesterase, ADP P2Y12 receptor and IIb/IIIa receptor). We review here the efficacy and safety of the association of antiaggregants in most relevant clinical scenarios, including current clinical recommendations and an analysis of supportive evidence.
López Menchaca
Ramiro
R
Servicio de Medicina Interna, Hospital Universitario de la Princesa, Madrid, España.
Herrero Martínez
Juan María
JM
Suárez Fernández
Carmen
C
D050197:Atherosclerosis / Q000150:complications; D001281:Atrial Fibrillation / Q000150:complications; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D003327:Coronary Disease / Q000188:drug therapy; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D016491:Peripheral Vascular Diseases / Q000188:drug therapy; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000145:classification / Q000191:economics / Q000627:therapeutic use; D018570:Risk Assessment; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control*; D019851:Thrombophilia / Q000150:complications / Q000188:drug therapy* / Q000209:etiology
D010975:Platelet Aggregation Inhibitors